New pill shows promise for Tough-to-Treat leukemia

NCT ID NCT04666259

Completed Disease control Sponsor: Novartis Pharmaceuticals Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 2 times

Summary

This study tested a new drug called asciminib in 56 adults with chronic myeloid leukemia (CML) whose cancer had not responded well to other treatments. The drug is taken as a pill and aims to control the disease. The main goal was to check safety and side effects over 24 weeks, with longer follow-up at 48 weeks. Results help understand if asciminib is a useful option for patients who have tried other therapies.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: asciminib
What this could lead to: If successful, asciminib could offer a new oral treatment option for patients with chronic myeloid leukemia who have not responded to other therapies.
What could go wrong: This is a relatively small Phase 3 trial (56 participants). Results may not apply to all patients, and side effects or lack of long-term benefit remain possible.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CHRONIC MYELOGENOUS LEUKEMIA - CHRONIC PHASE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

chronic myelogenous leukemia, BCR-ABL1 positive Leukemia, Myeloid, Chronic-Phase

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CHRONIC MYELOGENOUS LEUKEMIA - CHRONIC PHASE

Contacts and locations

Locations

Alaska Oncology and Hematology

Anchorage, Alaska, 99508, United States
Arizona Oncology Associates

Phoenix, Arizona, 85016, United States
Cancer Institute of New Jersey

New Brunswick, New Jersey, 08901, United States
Cancer Treatment Centers of America

Phoenix, Arizona, 85027, United States
Florida Cancer Specialists

Sarasota, Florida, 34232, United States
Florida Cancer Specialists East

Stuart, Florida, 34994, United States
Florida Cancer Specialists Pan

Tallahassee, Florida, 32308, United States
Florida Cancer Specialists-North

St. Petersburg, Florida, 33705, United States
Indiana Blood and Marrow Institute

Beech Grove, Indiana, 46107, United States
Lundquist Inst BioMed at Harbor

Torrance, California, 90509-2910, United States
Medical College of Wisconsin

Milwaukee, Wisconsin, 53226, United States
Memorial Cancer Institute

Hollywood, Florida, 33021, United States
Michigan Med University of Michigan

Ann Arbor, Michigan, 48109 5271, United States
Northwest Cancer Specialists

Portland, Oregon, 97210, United States
Oncology Hematology Care Inc

Cincinnati, Ohio, 45242, United States
Pacific Shores Medical Group

Long Beach, California, 90813, United States
Rocky Mountain Cancer Centers

Boulder, Colorado, 80304, United States
Siteman Cancer Center

St Louis, Missouri, 63110, United States
Texas Oncology

Dallas, Texas, 75251, United States
Texas Oncology Northeast Texas

Tyler, Texas, 75702, United States
Texas Oncology P A

Fort Worth, Texas, 76104, United States
Uni of Cincinnati Medical Center

Cincinnati, Ohio, 45219, United States
Uni of Massachusetts Medical Center

Worcester, Massachusetts, 01655, United States
Univ of TX MD Anderson Cancer Cntr

Houston, Texas, 77030, United States
University of Kentucky

Lexington, Kentucky, 40536, United States
Wake Forest University Baptist Medical Center

Winston-Salem, North Carolina, 27157, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.